J&J says late-stage COVID-19 vaccine trial fully enrolled – Reuters

By Reuters Staff
Dec 17 (Reuters) – Johnson & Johnson said on Thursday it has fully enrolled participants for the first late-stage trial of its COVID-19 single-dose vaccine candidate.
The study, named Ensemble, has enrolled about 45,000 participants and is being conducted by its unit Janssen, J&J said here in a statement, adding that it expects interim data from the trial by the end of January 2021.
J&J also said it plans to submit an emergency use authorization application to the U.S. Food and…

Click here to view the original article.